Okapi Sciences Enters Into a License Agreement with Novartis Animal Health
News Aug 27, 2013
Okapi Sciences NV has announced that it has entered into an exclusive agreement with Novartis Animal Health for the joint development and commercialization of an antiviral treatment for cats.
This novel drug will potentially be the world’s first antiviral small molecule specifically developed for veterinary use.
In close collaboration with Novartis Animal Health, Okapi Sciences is responsible for finalizing the clinical development work and applying for marketing authorization at the European Medicines Agency and the US Food and Drug Administration.
Under the terms of the agreement Okapi Sciences will receive payments if milestones are achieved, as well as royalties on any eventual sales of the product. Financial details were not disclosed.
Erwin Blomsma, CEO of Okapi Sciences, commented: “Today's collaborative deal with Novartis Animal Health is a major milestone for Okapi Sciences. Novartis Animal Health is the ideal partner for our product.”
Nesya Goris, chief scientist at Okapi Sciences, added: “It is exciting to join forces with the Novartis team in bringing this antiviral drug through the final stage of development and into the market.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Anti-Malaria Drugs Delivered With CaffeineNews
Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.READ MORE
Deadly Mushroom Toxin Helps Fight Cancer?News
The death-cap mushroom has a long history as a tool of murder and suicide, going back to ancient Roman times. While it may seem ill-advised, researchers are eager to synthesize the toxin because studies have shown that it could help fight cancer. Scientists now report how they overcame obstacles to synthesize the death-cap killer compound.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018